Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
TARS | US
0.48
0.79%
Healthcare
Biotechnology
30/06/2024
24/04/2026
61.45
61.07
62.67
60.22
Tarsus Pharmaceuticals Inc. a biopharmaceutical company focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03 a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition the company develops lotilaner to address diseases across therapeutic categories in human medicine including eye care dermatology and other diseases. Tarsus Pharmaceuticals Inc. was incorporated in 2016 and is headquartered in Irvine California.
View LessStrength based on increasing price with high volume
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
Price Below SMA10D
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
34.3%1 month
43.6%3 months
45.1%6 months
40.1%-
-
5.59
0.29
0.19
-3.23
13.90
-
-155.27M
2.34B
2.34B
-
-81.60
-
1.00K
-75.04
14.63
27.12
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
14.49
Range1M
14.49
Range3M
20.10
Rel. volume
1.46
Price X volume
42.90M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Relay Therapeutics Inc. | RLAY | Biotechnology | 15.13 | 2.46B | 0.27% | n/a | 7.50% |
| Kodiak Sciences Inc | KOD | Biotechnology | 44.84 | 2.36B | -0.82% | n/a | 81.94% |
| Arcus Biosciences Inc | RCUS | Biotechnology | 25.5 | 2.33B | 1.47% | n/a | 1.73% |
| Zai Lab Limited | ZLAB | Biotechnology | 22.77 | 2.31B | 4.07% | n/a | 11.88% |
| Aurinia Pharmaceuticals Inc | AUPH | Biotechnology | 15.98 | 2.28B | -0.99% | n/a | 23.58% |
| Spruce Biosciences Inc | SPRB | Biotechnology | 54.37 | 2.25B | 0.67% | n/a | 6.24% |
| BEAM THERAPEUTICS INC. | BEAM | Biotechnology | 27.11 | 2.23B | -10.11% | n/a | 19.35% |
| Ultragenyx Pharmaceutical Inc | RARE | Biotechnology | 24.1 | 2.22B | -0.74% | n/a | 214.27% |
| Celldex Therapeutics Inc | CLDX | Biotechnology | 33.29 | 2.21B | -0.77% | n/a | 0.29% |
| DBV Technologies S.A | DBVT | Biotechnology | 19.8 | 2.11B | 2.38% | n/a | 16.59% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| HNI Corporation | HNI | Building Products & Equipment | 37.7 | 1.78B | 1.32% | 22.12 | 76.47% |
| ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 14.6 | 1.46B | 3.03% | n/a | 19.46% |
| Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 39.11 | 1.23B | -1.21% | 51.60 | 88.92% |
| Winnebago Industries Inc | WGO | Recreational Vehicles | 32.87 | 951.75M | 0.70% | 22.53 | 56.33% |
| Janus International Group Inc. | JBI | Building Products & Equipment | 5.44 | 790.55M | 1.30% | 11.62 | 116.21% |
| Fox Factory Holding Corp | FOXF | Recreational Vehicles | 17.7 | 737.79M | 2.31% | 42.05 | 64.69% |
| Latham Group Inc. | SWIM | Building Products & Equipment | 6.01 | 694.62M | -0.17% | 65.18 | 77.00% |
| Ennis Inc | EBF | Building Products & Equipment | 20.33 | 528.66M | -1.26% | 13.28 | 2.28% |
| Malibu Boats Inc | MBUU | Recreational Vehicles | 26.1 | 521.76M | -0.91% | n/a | 1.50% |
| MCBC Holdings Inc | MCFT | Recreational Vehicles | 23.53 | 390.77M | -0.88% | 34.27 | 26.82% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.23 | - | Cheaper |
| Ent. to Revenue | 13.90 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 5.59 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 45.14 | - | Lower Risk |
| Debt to Equity | 0.29 | -1.23 | Expensive |
| Debt to Assets | 0.19 | 0.25 | Cheaper |
| Market Cap | 2.34B | - | Emerging |